Orca Bio is a late-stage biotechnology company focused on developing high-precision cell therapies for cancer and autoimmune diseases. Its investigational allogeneic T-cell programs leverage regulatory T cells to pursue safer, more effective outcomes. The company emphasizes precise manufacturing and a patient-centric mission to deliver the promise of cell therapy without compromise, with operations and pipeline exploration centered on biomedical advances in life sciences.
No recent deals for this company.